# Paratus Investment

> Paratus Investment is a VC fund backing Biotechnology, Medical and Pharmaceutical. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 14
- Last investment: Aug 2025
- Lead investor: 14%
- Last updated: Aug 2026
- Website: http://paratusinvestment.com/

Paratus Investment is a Private Equity Fund.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 43% |
| Medical | 4 | 29% |
| Pharmaceutical | 4 | 29% |
| Content | 2 | 14% |
| Health Care | 2 | 14% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 50% |
| Series A | 5 | 36% |
| Seed | 1 | 7% |
| Private Equity | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 8 | 57% |
| United States | 2 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MicrobiotiX | MicrobiotiX develops bacteriophage and microbiome-based therapeutics to combat multidrug-resistant infections and autoimmune diseases. | $3.6M | Series B | Aug 29, 2025 |  |
| DAAN Biotherapeutics | DAAN Biotherapeutics develops novel treatments for cancer patients. The company conducts cancer treatment research and development, including cell therapies, antibodies, and small molecule inhibitors. | $17.2M | Series A | Jan 25, 2024 |  |
| Ideahub | Ideahub is a technology company providing digital content and platform solutions for media, marketing, and business operations. The company offers technology-driven services that support content creation, digital communication, business innovation, and platform development, helping organizations improve customer engagement and operationalefficiency across various industries. | $5.4M | Series B | Apr 01, 2023 |  |
| AiV | AiV is a technology company focused on developing advanced AI and deep learning solutions for industrial applications. It specializes in computer vision systems used for automation, inspection, and smart manufacturing processes. The company aims to improve industrial efficiency by combining AI software, data analytics, and machine learningtechnologies. | $7.9M | Series B | Dec 29, 2022 |  |
| UPPTHERA | UPPTHERA is a pharmaceutical company that specializes in drug development using targeted protein degradation technology. | $21.9M | Series B | May 18, 2022 |  |
| Genome Insight | Genome Insight is a whole genome sequence (WGS) analysis and interpretation company. | $23M | Series B | Apr 28, 2022 |  |
| Inocras | Inocras Inc. specializes in whole genome sequencing and analytics, focusing on providing insights for personalized care in cancer and rare diseases. Utilizing artificial intelligence, Inocras aims to revolutionize healthcare by enabling precision medicine. The company offers services to patients, healthcare providers, researchers, and partners,seeking to unlock new possibilities in precision health. With a commitment to innovation, Inocras has introduced products like CancerVision and RareVision, designed to enhance diagnosis and treatment strategies through comprehensive genomic analysis. | $23M | Series B | Apr 28, 2022 |  |
| DAAN Biotherapeutics | DAAN Biotherapeutics develops novel treatments for cancer patients. The company conducts cancer treatment research and development, including cell therapies, antibodies, and small molecule inhibitors. | $4.1M | Seed | Mar 28, 2022 |  |
| VA Corporation | VA Corporation is a media and entertainment company. It is involved in virtual production, VFX, virtual human characters, and the planning and production of original film and drama content. The company is building a global content and metaverse ecosystem for or metaverse content production. It also specializes in an original content IP library. | $80.5M | Series A | Mar 14, 2022 |  |
| Cyrus Therapeutics | Cyrus Therapeutics is a biotechnology company that discovers and develops molecule medicines to conquer chronic diseases. | $24.1M | Series B | Jan 27, 2022 |  |

10 of 14 investments shown.

## Co-investors
- [DSC Investment](https://shizune.co/investors/profile/dsc-investment) — VC Fund, 4 deals together
- [Schmidt](https://shizune.co/investors/profile/schmidt-4d8d) — VC Fund, 4 deals together
- [Timepolio Asset Management](https://shizune.co/investors/profile/timepolio-asset-management) — VC Fund, 4 deals together
- [Atinum Partners](https://shizune.co/investors/profile/atinum-partners) — VC Fund, 2 deals together
- [Company K Partners](https://shizune.co/investors/profile/company-k) — VC Fund, 2 deals together
- [Dunamu & Partners](https://shizune.co/investors/profile/dunamu-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Paratus Investment invest in?

Paratus Investment invests primarily in Biotechnology, Medical and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Paratus Investment last invest?

The most recent investment recorded for Paratus Investment closed in Aug 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co